Pay in 4 interest-free payments of $6.52 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Make meals smaller but don't skip them entirely
trials show that GLP-1 RAs decrease inflammatory markers, improve endothelial function, and decrease arterial stiffness
Some insurers now cover Wegovy specifically for cardiovascular risk reduction in patients with established heart disease and obesity, even when their weight-loss-only formulary excludes it
GLP-1 receptor agonists mimic the action of naturally occurring hormones that regulate blood glucose and appetite by: Slowing gastric emptying, promoting feelings of fullness Reducing appetite signals in the brains hunger centers Improving insulin secretion while suppressing glucagon release Creating a caloric deficit through reduced food intake Originally developed for type 2 diabetes management, these medications have gained FDA approval for chronic weight management in adults with obesity or overweight with weight-related comorbidities
Ponirakis G, Abdul-Ghani MA, Jayyousi A, Zirie MA, Qazi M, Almuhannadi H, Petropoulos IN, Khan A, Gad H, Migahid O, Megahed A, Al-Mohannadi S, AlMarri F, Al-Khayat F, Mahfoud Z, Al Hamad H, Ramadan M, DeFronzo R, Malik RA (2021) Painful diabetic neuropathy is associated with increased nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control
Timing your injections Both medications are administered once weekly
